Edesa Biotech appoints Peter J. Weiler as Chief Financial Officer starting May 1, 2025, to enhance drug development efforts for immuno-inflammatory diseases. Weiler brings extensive pharmaceutical experience, previously holding key…
Edesa Biotech announces Peter J. Weiler as its incoming Chief Financial Officer, effective May 1, 2025. Weiler transitions from his role as President of Exzell Pharma, bringing strategic expertise in…
Edesa Biotech announces a leadership change, appointing Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Weiler's strategic and industry expertise, bolstered by roles at Exzell Pharma and…
Edesa Biotech announces Peter J. Weiler as the new CFO, signifying a strategic leadership shift. Weiler brings extensive experience in finance, biology, and business from his roles at Exzell Pharma,…
Edesa Biotech has announced a strategic leadership change, appointing Peter J. Weiler as Chief Financial Officer effective May 1, 2025. Weiler brings extensive experience from roles at Exzell Pharma, Biosyent…
Edesa Biotech appoints Peter J. Weiler as Chief Financial Officer, effective May 1, 2025, marking a significant leadership change. Weiler succeeds Stephen Lemieux, who transitions to an advisory role, maintaining…
Edesa Biotech undergoes a pivotal leadership change as Peter J. Weiler replaces Stephen Lemieux. Weiler brings extensive experience from leadership roles at Exzell Pharma, Biosyent Inc., and Cipher Pharmaceuticals. His…
Peter J. Weiler is appointed CFO of Edesa Biotech starting May 1, 2025, marking a strategic leadership transition. Weiler brings extensive experience from roles in biotech and pharmaceuticals, previously as…
Edesa Biotech appoints Peter J. Weiler as Chief Financial Officer, signaling strategic financial enhancement amidst leadership transitions. Weiler's extensive experience in biotech and pharmaceuticals, highlighted by his role at Exzell…
Edesa Biotech appoints Peter J. Weiler as CFO starting May 1, 2025, succeeding Stephen Lemieux. Weiler brings extensive experience from leadership roles at Exzell Pharma and Biosyent Inc., blending scientific…